Phase 1 Study of WBRT or PCSI With REYOBIQ for Leptomeningeal Metastases
2026年6月23日 更新者:NYU Langone Health
A Phase 1 Study to Determine the Safety and Tolerability of Whole Brain Radiotherapy (WBRT) or Proton Craniospinal Irradiation (PCSI) With Multiple Doses of Rhenium-186 NanoLiposome (186RNL, REYOBIQ) Administered Via Intraventricular Catheter for Leptomeningeal Metastases
This Phase 1 study is designed to assess the safety, tolerability, and schedule feasibility of administering Rhenium-186 NanoLiposome (REYOBIQ) at different dosing intervals following whole brain radiotherapy (WBRT) or proton craniospinal irradiation (PCSI).
研究概览
研究类型
介入性
注册 (估计的)
29
阶段
- 阶段1
联系人和位置
本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。
学习联系方式
- 姓名:Cancer Trials Inbox
- 邮箱:CancerTrials@nyulangone.org
研究联系人备份
- 姓名:Jonathan Yang, MD, PhD
- 电话号码:2127316030
- 邮箱:Jonathan.Yang@nyulangone.org
参与标准
研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。
资格标准
适合学习的年龄
- 成人
- 年长者
接受健康志愿者
不
描述
Inclusion Criteria:
- At least 18 years of age at screening
- Ability to understand the purposes and risks of the study and has signed a written informed consent document approved by the site-specific IRB
- Proven and documented LM evidenced by positive CSF cytology or CSF circulating tumor cells, from any primary solid tumor
- Patients may have received prior chemotherapy regimens and prior radiation (there is no limit)
- Karnofsky performance status of 60 to 100
Acceptable liver function:
- Bilirubin ≤ 1.5 times upper limit of normal
- AST (SGOT) and ALT (SGPT) ≤ 3.0 times upper limit of normal for subjects with normal liver
- AST (SGOT) and ALT (SGPT) ≤ 5.0 times upper limit of normal for subjects with liver metastasis
- Subjects with a creatinine clearance greater than or equal to 60 mL/min (using the Cockcroft-Gault Equation) for males and females.
Acceptable hematologic status (without hematologic support):
- ANC ≥ 1000 cells μL
- Platelet count ≥ 75,000/μL
- Hemoglobin ≥ 9.0 g/dL
- PT/INR and PTT ≤1.5 x ULN, unless treated with anticoagulants
- All women of childbearing potential must have a negative serum pregnancy test at screening. Male and female subjects must agree to use effective means of contraception (for example, surgical sterilization or the use of barrier contraception with either a condom or diaphragm in conjunction with spermicidal gel or an IUD) with their partner from entry into the study through 6 months after the last dose.
Exclusion Criteria:
- The subject has not recovered to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE v6.0) Grade ≤ 1 from AEs due to antineoplastic agents, investigational drugs, or other medications that were administered prior to study. Prior AEs due to alopecia, anemia, and lymphopenia are not required to be recovered to Grade ≤ 1 prior to 186RNL treatment, assuming other inclusion criteria are satisfied.
- Ventriculo-peritoneal or ventriculo-atrial shunts or contraindications to placement of Ommaya reservoir.
- Females of childbearing potential who are pregnant, breast feeding, or may possibly be pregnant without a negative serum pregnancy test (see inclusion criteria).
- Serious intercurrent illness, clinically significant cardiac arrhythmias, uncontrolled systemic infection, symptomatic congestive heart failure or unstable angina pectoris within 3 months prior study drug, myocardial infarction, stroke, transient ischemic attack within 6 months, seizure disorder with any seizure occurring within 14 days prior to consenting or encephalopathy.
- Active severe non hematologic organ dysfunction such as renal, cardiac, hepatic, pulmonary, or gastrointestinal grade 3 or above.
- Toxicity from prior treatments (grade 3 or above) that have not subsided to grade 1.
- Patients with prior CNS directed EBRT.
- Cytotoxic systemic therapy is excluded if given within 14 days or 5 half-lives, whichever is shorter, prior to 186RNL treatment. Small-molecule kinase inhibitors, targeted therapies, immunotherapy, and hormonal therapy can be given up to the day of treatment per investigator discretion.
- Projected survival of less than 60 days.
学习计划
本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:不适用
- 介入模型:单组作业
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:WBRT or PCSI followed by REYOBIQ
Patients will undergo WBRT or PCSI; following WBRT or PCSI, patients will initiate REYOBIQ in 28 (+/- 7 days) days following a dose escalation scheme.
|
Intraventricular injection via catheter. Patients will be assigned to three separate dosing schedules and once assigned they will remain on that dose level for up to 12 months (6 doses). Each dose will be 26.4 mCi, and participants will receive three doses for a total of 79.2 mCi. The time between doses will vary depending on the schedule (shown in table 1):
其他名称:
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Incidence of Dose-Limiting Toxicities (DLTs)
大体时间:Up to Month 13 (28 Days Post-Final Dose)
|
The incidence of DLTs during the 28-day DLT window following any administration of REYOBIQ.
|
Up to Month 13 (28 Days Post-Final Dose)
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Central Nervous System Progression-Free Survival (CNS PFS)
大体时间:Up to Year 5
|
Defined as the time from first treatment to the date of leptomeningeal metastases (LM) progression or death from any cause, whichever occurs first.
|
Up to Year 5
|
|
Overall Survival (OS)
大体时间:Up to Year 5
|
Defined as the time from first treatment to death from any cause.
|
Up to Year 5
|
|
Overall Response Rate (ORR)
大体时间:Up to Year 5
|
Defined as the proportion of evaluable patients achieving a best overall response (complete or partial response) prior to progression.
|
Up to Year 5
|
|
Duration of Response (DoR)
大体时间:Up to Year 5
|
Defined as the time from first treatment to the date of LM progression among responders.
|
Up to Year 5
|
合作者和调查者
在这里您可以找到参与这项研究的人员和组织。
调查人员
- 首席研究员:Jonathan Yang, MD, PhD、NYU Langone Health
研究记录日期
这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。
研究主要日期
学习开始 (估计的)
2026年7月1日
初级完成 (估计的)
2028年7月1日
研究完成 (估计的)
2031年7月1日
研究注册日期
首次提交
2026年6月18日
首先提交符合 QC 标准的
2026年6月23日
首次发布 (实际的)
2026年6月29日
研究记录更新
最后更新发布 (实际的)
2026年6月29日
上次提交的符合 QC 标准的更新
2026年6月23日
最后验证
2026年6月1日
更多信息
与本研究相关的术语
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
是的
IPD 计划说明
The de-identified participant data from the final research dataset will be shared upon reasonable request beginning 9 to 36 months after publication or as required by a condition of awards or supporting agreements, provided the requesting investigator executes a data use agreement with NYU Langone Health.
This instance of data sharing will also require separate IRB review as well as review from NYU Langone's Data Sharing Strategy Board (DSSB).
Requests should be directed to: Jonathan.Yang@nyulangone.org.
The protocol and statistical analysis plan will be posted on Clinicaltrials.gov
only as required by federal regulation or supporting awards and agreements.
IPD 共享时间框架
Beginning 9 months and ending 36 months following article publication or as required by a condition of awards and agreements supporting the research.
IPD 共享访问标准
Requests should be directed to Jonathan.Yang@nyulangone.org.
To gain access, data requestors will need to sign a data access agreement.
This instance of data sharing will also require separate IRB review as well as review from NYU Langone's DSSB.
IPD 共享支持信息类型
- 研究方案
- 树液
药物和器械信息、研究文件
研究美国 FDA 监管的药品
是的
研究美国 FDA 监管的设备产品
不
在美国制造并从美国出口的产品
不
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.